The shares of Eisai Co. climbed up as much as 1.7 percent to 2,916 yen after USFDA approved its breast cancer treatment.
Federal health regulators had approved the eribulin mesylate treatment for aggressive form of breast cancer.
The drug will be available with the brand name Halaven, and it is formed using a substance obtained from a sea sponge.
According to the National Cancer Institute, around 207,000 women in the U. S are diagnosed with breast cancer this year.
The illness is blamed for 40000 deaths in the country.
During the clinical trial conducted in 762 women, Halaven extended the survival time of women with advanced breast cancer by two and a half months as compared to present single-agent therapies.
Richard Pazdur, director of the FDA’s Office of Oncology Drug Products, said, “Halaven shows a clear survival benefit and is an important new option for women.”
The treatment is beneficial for those women who have already undergone other chemotherapy treatments for treating metastatic breast cancers.
The side effects associated with the drug were a decrease in white blood cells, anemia, hair loss, fatigue, nausea, nerve damage and constipation.